港股异动|彩客化学涨逾7%中期纯利同比增长234.7%
格隆汇8月27日丨彩客化学(1986.HK)午后上扬,现报2.68港元,涨7.2%,暂成交1170万港元,最新总市值27.858亿港元。彩客化学于上周五(23日)晚间公布中期业绩称,期内公司收益10.75亿元(人民币,下同),同比增长42.5%;毛利6.7亿元,同比增长161.2%;纯利4.07亿元,同比增长234.7%;每股盈利0.39元,不派息。分析人士指其净利润增长超2倍,盈利能力增长强劲,资产负债率大幅下降,近四年收入稳定增长,复合增长率达到约29.1%。总体来看,彩客化学目前估值水平徘徊在历史低洼位置,近期彩客化学估值有望形成重估。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.